News and reporting on prostate cancer.
Bringing together more than 1,000 prostate cancer exomes, researchers uncovered almost 100 significantly mutated genes, including drivers mutated in a fraction of tumors.
The technology will measure cancer-associated miRNAs using optical amplification with quantum dots and photonic crystals.
Under the draft determination, the test would be covered to help assess which treatments to use in patients with advanced prostate cancer.
The companies will co-fund a new study of the 3DS technology, and MDxHealth will have the option to exclusively license the telomere-based test.
A Harvard genetics professor says that in spite of a history of misuse of genetics in discussions about race, scientists should not shy away from the conversation as long as it's done responsibly and scientifically.
The Fondazione Luigi Maria Monti - Istituto Dermopatico dell' Immacolata research hospital in Rome will perform SelectMDx testing locally.
The project allows prostate cancer patients to provide their de-identified clinical and genomic data to the research community.
Excluding the sale of the company's colorectal cancer patents to Exact Sciences, its 2017 revenues rose 13 percent.
The updated recommendations discuss testing for DNA repair gene mutations, MSI-H, and dMMR, as well as germline testing and counseling.
A family-based analysis led to an X chromosome variant in MAGEC3 that appeared to contribute to early-onset ovarian cancer risk in sisters and their paternal grandmothers.
Rady Children's Institute for Genomic Medicine and Deloitte are looking into the use of drones to transport samples for testing.
Direct-to-consumer genetic testing firm 23andMe is laying off about 100 people.
Researchers from Northwestern University examined dust for antibiotic-resistance genes, New Scientist reports.
In Science this week: researchers present a computational method for predicting cellular differentiation state from single-cell RNA sequencing data, and more.